Navigation Links
DaVita Clinical Research Completes Record Number of Renal Trials in 2007
Date:5/8/2008

Nation's Largest Renal Research Network Completes 13 Phase-I Clinical

Trials; Reports Another 34 Active Trials in Late Stage Development

EL SEGUNDO, Calif., May 8 /PRNewswire/ -- DaVita Clinical Research(R) (DCR), a Phase I-IV clinical trial research service business specializing in renal-related drug and device research and development for FDA approval, reports it completed 13 Phase-I clinical trials in 2007 and has another 34 active trials in late stage drug development-a company record.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

DCR(R), through its commitment to quality, timely and accurate clinical trials, plays a valuable role by partnering with physicians, pharmaceutical and biotechnology companies to develop and progress new drug therapies for patients diagnosed with chronic kidney disease (CKD). The increase in completed and late stage trials also serves as an indication of continued innovation and investment for end stage renal disease (ESRD) research.

"The recent DaVita Clinical Research accomplishments can be attributed to our continuous research quality index measurements and commitment to service excellence," said Chris Rucker, DCR Vice President and General Manager. "These values serve as a catalyst for our research objectives, and allow us to participate in the advancement of renal knowledge and practice."

DCR has nearly two decades of experience in conducting Phase I-IV clinical trials, and is the nation's largest renal research network dedicated to providing and supporting clinical and data research. DCR provides Phase-I renal studies services including renal, Hepatic, CV, Dermatology and Endocrine subjects, Pharmacokinetics, Pharmacodynamics and drug interactions. Phase II- IV renal studies services include pre ESRD and ESRD subjects, clinical efficacy and safety, special populations and post marketing studies.

"Since departing full-time academics for private practice, DaVita Clinical Research has helped me to continue my clinical research efforts," said Robert I. Lynn, M.D. of Nephrology & Hypertension Associates. "The staff locates high quality studies and makes it easier to do clinical trials in DaVita(R) facilities. They are friendly, responsive and supportive, and DaVita Clinical Research really does work with you not only to get a research effort 'off the ground,' but also to help it develop and prosper."

DaVita and DaVita Clinical Research are registered trademarks of DaVita Inc. All other trademarks are the properties of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages more than 1,300 outpatient facilities and acute units in more than 700 hospitals located in 43 states and the District of Columbia, serving approximately 107,000 patients. For more information about DaVita and its kidney education programs, please visit http://www.davita.com.


'/>"/>
SOURCE DaVita Clinical Research
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
2. Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests
3. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
4. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
5. Go Healthy Initiates Additional Clinical Tests on Cholesterade
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
8. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
9. NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
10. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
11. Association of Clinical Research Organizations (ACRO) to Help Lead Clinical Trials Transformation Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... stories, courtesy of leaders in the nursing and health care industry. It also ... advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... Florida (PRWEB) , ... May 26, 2016 , ... ... House® Project offering a new model of care for living and healing, celebrated ... core values: Meaningful Life in a Real Home provided by Empowered Staff. , “This ...
Breaking Medicine News(10 mins):